Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy

Not Applicable

Not yet recruiting

• Conditions: Lung Cancer (Diagnosis)

• Registration Number: NCT07241182
• Lead Sponsor: Tri-Service General Hospital

Brief Summary

This randomized trial will test whether Antrodia cinnamomea supplement improves quality of life in lung cancer patients receiving platinum-based chemotherapy.

Participants at Tri-Service General Hospital will be randomized to receive either Antrodia cinnamomea capsules or placebo for 3 months, with follow-up to 6 months (24 weeks). Primary outcomes include nausea/vomiting scores, sleep quality, quality of life, and cancer symptoms.

Detailed Description

This study will test whether a nutritional supplement, Antrodia cinnamomea can help improve quality of life in lung cancer patients receiving platinum-based chemotherapy.

Lung cancer patients often experience side effects from chemotherapy treatment, including nausea, vomiting, sleep problems, and other symptoms that affect their daily life. Antrodia cinnamomea is a medicinal mushroom supplement that may help reduce these side effects.

The study will include lung cancer patients who are receiving platinum-based chemotherapy at Tri-Service General Hospital. Participants will be randomly assigned to one of two groups: Participants will be randomly assigned to one of two groups: half will receive capsules containing turmeric, probiotics, and Antrodia cinnamomea, and half will receive capsules containing only turmeric and probiotics. Neither participants nor doctors will know which treatment each person is receiving.

All participants will take their assigned capsules daily for 3 months. Researchers will then continue to follow participants for an additional 3 months (up to 6 months total or 24 weeks) to monitor the lasting effects of the supplement. During this time, researchers will use questionnaires to measure nausea and vomiting, sleep quality, and cancer-related symptoms. The study will compare these measurements between the two groups to see if Antrodia cinnamomea supplement helps improve quality of life.

Study Timeline

• Study First Submitted: 2025-09-04
• Status Verified: 2025-11
• Study First Submitted QC: 2025-11-19
• Last Update Submitted: 2025-11-19
• Study First Posted: 2025-11-21
• Last Update Posted: 2025-11-21
• Study Start: 2025-11-24
• Primary Completion: 2027-03-31
• Study Completion: 2027-09-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Pathologically and radio-graphically diagnosed lung cancer
• Age greater than 18 years
• Received platinum-based chemotherapy
• Life expectancy of six months or longer

Exclusion Criteria

• Inability to comply with timely supplementation administration.
• Within 14 days prior to trial entry, laboratory data showing abnormal liver function, abnormal kidney function
• Within 30 days prior to trial entry, unexplained fever ≥38.5°C for 7 consecutive days or chronic diarrhea for 15 consecutive days.
• Currently receiving hormone therapy.
• Major cardiac disease or arrhythmia severe enough that the attending physician considers the patient unsuitable for trial participation.
• Major neuropathy.
• Patients with currently active acute infections.
• Patients with known allergies/allergic reactions to the investigational product or any components in their formulations.
• Patients currently taking supplements containing Antrodia camphorata extract.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Nausea and vomiting	Baseline, Week 3, Week 12, Week 18, and Week 24	The Rhodes index of nausea, vomiting and retching (RINVR) will be used. While each item is scored from 0 to 4, the total possible score on the 8-item index is 32, with higher scores indicating greater severity.
Sleep quality	Baseline, Week 12, and Week 24	Pittsburgh Sleep Quality Index (PSQI) will be used. Each component score of the PSQI ranges from 0 to 3, with the total possible score on the 7-component index being 21. The 0-3 scale assesses sleep dysfunction and disturbance, with higher scores indicating poorer sleep quality.
Symptom assessment	Baseline, Week 12, and Week 24	The MD Anderson Symptom Inventory (MDASI) will be used. MDASI contains 19 items scored from 0 to 10, assessing symptom severity (13 items) and interference with daily activities (6 items). Higher scores indicate greater symptom burden.
Overall quality of life	Baseline, Week 12, and Week 24	The EORTC QLQ-LC13 will be used. Each item on the 13-item EORTC QLQ-LC13 is scored from 1 to 4, assessing lung cancer-specific symptoms. Higher scores indicate greater symptom severity.

Secondary Outcome Measures

Name	Time	Method
Skeletal muscle mass	Baseline, Week 3, Week 12, Week 18, and Week 24	Skeletal muscle mass as measured by bioelectrical impedance analysis (BIA), reported in kilograms.